Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKayleigh McCloskeyJAJames AriesVMVarun Mehra

Discussion

Loading...

Member takes

Overview

Prospective analysis indicates improved survival and manageable complications in patients with DDX41-mutated myeloid neoplasms undergoing transplantation.

Key Points

  • Survival rates improved significantly, achieving one-year overall survival of 86.6% in older adults with DDX41-mutated myeloid neoplasms.
  • The study included 26 patients treated with reduced-intensity conditioning, highlighting effective transplantation strategies.
  • Conditions for all patients included acute graft-versus-host disease in 31.8% and manageable chronic GVHD in 27.3% of evaluable cases.
  • Findings support hematopoietic stem cell transplantation as a viable treatment option for this unique genomic subgroup.

Cite This Study

McCloskey et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b5https://doi.org/10.1182/blood-2025-6083
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies2025 · 7 citations
  2. 2Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients2025 · 1 citations
  3. 3DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre2025
  4. 4Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study2025
  5. 5Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)2025